FIG 2.

Primary antiviral evaluation of nucleoside analogs. (A) DENV replicon cell line. (B) JEV replicon cell line. All 14 nucleoside/nucleotide prodrug compounds (C1 to C14) were evaluated in the DENV and JEV replicon systems at five concentrations. Percent inhibition, relative to untreated controls, is plotted versus concentration for each compound. Of the 14 compounds tested, compounds 3, 5, and 10 exhibited significant inhibitory activity against JEV and compounds 5, 9, and 10 showed significant inhibitory activity against DENV-2 in a replicon cell line.